Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cimzia is a Fc-free anti-TNF treatment. Bimekizumab is a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F cytokines.

Reflecting UCB’s efforts to better understand the impact of psoriasis on patients, and the unique needs of women, UCB presented new results from a sample of almost 90,000 respondents of the World Psoriasis Happiness Surveys. These findings highlight gender as a strong predictor of psychological and social well-being in people living with psoriasis and PsA, more so than geographies. The analysis illustrates how psoriasis and PsA can negatively affect women more than men when it comes to life satisfaction, loneliness, mood and self-esteem. Worse life satisfaction, stress, loneliness and isolation were felt most in young women with psoriasis.

New Cimzia three-year efficacy data in plaque psoriasis from a pooled analysis of the completed CIMPASI-1 and CIMPASI-2 open-label extension Phase 3 studies were presented as an oral presentation. Additional pooled results from these trials include Cimzia 48-week sustained efficacy data in psoriasis of the head and neck, areas where disease manifestations can cause high degrees of emotional distress, particularly for female patients.

New 60-week data on novel investigational molecule bimekizumab, from the BE ABLE Phase 2 clinical development program, show rapid and sustained improvements in quality of life (as measured by the Dermatology Life Quality Index), which positively associate with clinical outcomes in patients with moderate-to-severe plaque psoriasis.iPositive scalp and nail disease outcomes at 60 weeks will also be presented, further supporting bimekizumab’s potential.